Rigel adds VEPPANU to portfolio, keeps R289 timeline, raises 2026 revenue guidance
The oncology and hematology company licensed the PROTAC breast cancer drug from Arvinas and Pfizer and expects U.S. launch in mid-August, while its R289 MDS trial stays on track for second-half 2026 dose selection.
SEC filing